Xanthine oxidase inhibitors for gout: Applications and novel drug development

Key Points

• Xanthine oxidase inhibitors show promise in reducing gout symptoms, with improved patient outcomes likely.
• Key evidence reveals that these inhibitors can lower serum urate levels by up to 40% in affected individuals.
• The analysis evaluates the molecular pathways impacted by xanthine oxidase inhibitors and their role in drug development.
• Future work may enable better-targeted treatments for gout, addressing limitations of current therapies and improving patient adherence.